Warner-lambert Company

Basf Aktiengesellschaft

Other

Abbvie Inc.

Basf Aktiengesellsschaft

Hamish John Allen

Kenneth Dale Brady

Catherine R Kostlan

Subhashis Banerjee

Robert V Talanian

Nigel P Walker

John C Hodges

William Glen Harter

Bruce D Roth

Tariq Ghayur

Bradley W Caprathe

Chengbin Wu

Elizabeth Ann Lunney

Joseph Scott Warmus

Sheryl Jeanne Hays

Mark Stephen Plummer

Rajesh Vasant Kamath

Margaret Hugunin

Lisa Maria Olson

Michael Paskind

Carolyn A Cuff

Tomi Sawyer

Peter C Isakson

Hans Peter Albrecht

Aurash B Shahripour

John Lodge Gilmore

Paul Galatsis

Ping Li

Tara Seshadri

The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.

Dual variable domain immunoglobulins and uses thereof

The present invention relates to compounds that are inhibitors of interleukin-1&bgr; converting enzyme that have the Formula (I). This invention also relates to a method of treatment of stroke, reperfusion injury, Alzheimer's disease, shigellosis, inflammatory diseases, and septic shock and to a pharmaceutically acceptable composition that contains a compound that is an inhibitor of interleukin-1&bgr; converting enzyme.

Sulfonamide interleukin-1&bgr; converting enzyme inhibitors

A transgenic mouse having somatic and germ cells in which at least one allele of an endogenous interleukin-1.beta. converting enzyme (ICE) gene is functionally disrupted is provided. The mouse may be heterozygous or, more preferably, homozygous for the ICE gene disruption. In homozygous mice, secretion of mature interleukin-1.beta. and interleukin-1.alpha. is substantially reduced relative to non-mutant mice. The mice of the invention can be used as positive controls to evaluate the efficacy of ICE inhibitors and to identify disease conditions that can be treated with ICE inhibitors. A transgenic mouse having functionally disrupted endogenous ICE genes but which has been reconstituted with a human ICE gene is also provided. This mouse can be used to identify agents that inhibit human ICE in vivo. Nucleic acid constructs for functionally disrupting an endogenous ICE gene in a host cell, recombinant vectors including the nucleic acid construct, and host cells into which the nucleic acid construct has been introduced are also encompassed by the invention.

Transgenic knockout mouse having functionally disrupted interleukin-1.beta.

Sulfonamide substituted aspartic acid interleukin-1.beta. converting

The present invention relates to N-substituted derivatives of glutamic acid of pharmaceutical interest, to pharmaceutical compositions which include compounds of the invention and pharmaceutically acceptable carriers, to methods of their preparation, and to their use in purification of interleukin-1.beta. converting enzyme (ICE).

N-substituted glutamic acid derivatives with interleukin-1.beta.

The present invention relates to compounds that are inhibitors of interleukin-1.beta. converting enzyme that have the Formula II ##STR1## This invention also relates to a method of treatment of stroke, inflammatory diseases, septic shock, reperfusion injury, Alzheimer's disease, shigellosis, and to a pharmaceutically acceptable composition that contains a compound that is an inhibitor of interleukin-1.beta. converting enzyme.

Hydroxamate inhibitors of interleukin-1.beta. converting enzyme

N-substituted glutamic acid derivatives with interleukin-1 .beta.

Growing community of inventors

Boylston, MA, United States of America

Hamish John Allen